AMBS News Alert Amarantus Biosci Inc (AMBS) 0.0875 09/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amarantus Biosci Inc (AMBS) 0.0875 $AMBS

Amarantus BioScience Holdings, Inc. - "Fundamental Milestones Ahead: Up-Listing from Strength"
ACCESSWIRE - Thu Sep 18, 12:05PM CDT
New York, NY / ACCESSWIRE / September 18, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Market Maker Surveillance Report. TIVO, MDT, CTSH, RHHBY, NVLX, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. TIVO INCORPORATED (NASDAQ:TIVO), Medtronic Inc (NYSE:MDT), Cognizant Technology Solutions Corp (NASDAQ:CTSH), Roche Holding AG (OTC:RHHBY), Nuvilex Inc (OTC:NVLX), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Amarantus Provides Program Update on Phase 2b Eltoprazine for Parkinson's Disease and Adult ADHD
GlobeNewswire - Wed Sep 17, 8:28AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today provided a program update on its Phase 2b-ready Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia patients ("PD LID" and adult attention deficit and hyperactivity disorder ("Adult ADHD" . The company expects to initiate its Phase 2b PD LID clinical trial in the fourth quarter of 2014 or early in 2015.

Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)
GlobeNewswire - Fri Sep 12, 9:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that it has completed enrollment of the originally planned 72 patient LP-002 clinical study to assess the commercial feasibility of the company's flagship Alzheimer's blood diagnostic LymPro Test(R). Amarantus previously released positive interim data from LP-002 on July 31, 2014 and expects to release data on the predictive value of individual LymPro markers (univariate) from the full cohort of 72 patients in the coming weeks.

Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014
GlobeNewswire - Wed Sep 10, 12:00PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that Dr. Roman Urfer, Chief Development Officer at NeuroAssets Sarl, will be presenting efficacy data for MANF in an undisclosed orphan ocular indication at Targeting Ocular Disorders 2014. NeuroAssets is a Swiss-based neuroscience-focused consulting firm engaged by Amarantus to support the translational development of MANF. Dr. Urfer's presentation will be made at 3:40pm ET on October 6, 2014 at the Westin Boston Waterfront Market in Boston, MA.

Amarantus Announces Positive MANF Ocular Toxicology Data
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced positive 15-day non-GLP toxicology data for a single intravitreal administration of MANF in an ocular safety animal model, relevant to MANF's development in ocular diseases, including orphan indications such as Retinitis Pigmentosa. The intravitreal method of administration was chosen because it is the delivery method expected for human application of MANF. The experiments were conducted at a leading ophthalmology contract research laboratory in France.

Market Maker Surveillance Report. AMAT, BAC, SIRI, AAPL, CNC, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 3rd 2014
M2 - Thu Sep 04, 10:09AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4918 companies with "abnormal" market making, 2306 companies with positive Friction Factors and 2830 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. APPLIED MATERIALS, INC. (NASDAQ:AMAT), BANK OF AMERICA CORPORATION (NYSE:BAC), Sirius XM Radio Inc (NASDAQ:SIRI), Apple Inc (NASDAQ:AAPL), CENTENE CORPORATION (NYSE:CNC), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Amarantus to Present at Sachs Associates 14th Annual Biotech in Europe Forum for Global Partnering and Investment
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, announced that Gerald E. Commissiong, President and CEO, is scheduled to present at the 14 Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for Wednesday, October 1 at 11:45 AM in the Darwin Room. Mr. Commissiong's presentation will be web cast live and available on the company's web site at www.amarantus.com.

Amarantus BioScience Holdings, Inc. - "Initiating Studies for CLIA Launch at Icon Central Laboratories"
ACCESSWIRE - Tue Sep 02, 7:26AM CDT
New York, NY / September 2, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Amarantus Initiates CLIA Development of Alzheimer's Blood Diagnostic LymPro Test(R) at ICON Central Laboratories
GlobeNewswire - Tue Sep 02, 5:14AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, announced it has entered into a Master Services Agreement with ICON for global therapeutic and diagnostic clinical development services. Amarantus has submitted an initial work order to ICON for delivery of the Fit for Purpose Flow Cytometry Assay Validation of the company's flagship Alzheimer's blood diagnostic LymPro Test(R) at ICON's CLIA-certified Central Laboratory facility in Farmingdale, NY.

Amarantus elects Iain Ross to board
M2 - Mon Sep 01, 3:29AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) revealed on Friday the addition of Iain Ross to its board of directors.

Amarantus Appoints Iain Ross to Board of Directors
GlobeNewswire - Fri Aug 29, 6:56AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced the appointment of Mr. Iain Ross to the Company's Board of Directors, Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amarantus across executive management, investment and directorship roles.

Amarantus Reports Second Quarter 2014 Financial Results, Announces Business Update Call
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, reported financial results for the second quarter ended June 30, 2014 and announced a business update call on September 2, 2014. At August 27, 2014, the Company had cash and cash equivalents totaling approximately $2.4 million.

Amarantus to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 19, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/.

Amarantus announces exercise of option to license intellectual property from University of Miami Bascom Palmer Eye Institute for retinal disorders
M2 - Mon Aug 18, 6:39AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday that it has exercised its exclusive perpetual option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute.

Amarantus Exercises Option to License Intellectual Property From University of Miami Bascom Palmer Eye Institute for Use of MANF in Retinal Disorders
GlobeNewswire - Fri Aug 15, 7:10AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced that it exercised its exclusive option to license intellectual property related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute, and has entered into an exclusive license for said intellectual property. Under the terms of the agreement, the Company has been granted a perpetual, exclusive worldwide license to intellectual property, covering the use of MANF for the treatment of retinal disorders, including Retinitis pigmentosa.

Amarantus BioScience Holdings, Inc. "Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy"
ACCESSWIRE - Mon Aug 11, 7:03AM CDT
New York, NY / ACCESSWIRE / August 11, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, co-written by the Company's CEO, Mr. Gerald Commissiong and Chief Financial Officer, Mr. Robert Farrell, JD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Amarantus Enters Into Research Collaboration With the Buck Institute for Research on Aging for MANF
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with theBuck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications. MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.

OTC Trading Stock News: Amarantus Biosciences Holdings, Inc. Virtus Oil and Gas Corp, Cannabis Sativa, Inc. Creative Edge Nutrition, Inc. DNA Brands, Inc.
PR Newswire Europe - Tue Aug 05, 7:03AM CDT
LONDON, August 5, 2014 /PRNewswire/ --




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 468

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 446

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Luxurious Mark Lane Apartments in Naples, FL

Updated Category News Views 205

Explore the Luxurious Mark Lane Apartments Mark Lane Apartments is a remarkable new residential community that has quickly established itself in the real estate market. A Class A+ Trophy Asset This impressive four-story concrete block building is a true trophy asset, featuring 286 spacious units, each averaging 1,050 square feet. The complex is situated on a generous...

Continue Reading
Major Revenue Surge: POP Culture Group's Impressive FY2025 Results

Updated Category News Views 226

POP Culture Group Achieves Record Revenue in FY2025 In a remarkable financial breakthrough, POP Culture Group Co., Ltd. (Nasdaq: CPOP) has announced its fiscal year 2025 results, showcasing an incredible revenue surge that exceeded $100 million for the first time. This milestone represents a significant leap, with revenue increasing by 127% compared to the previous fiscal...

Continue Reading
Jericho Wholesale and Shell Unite for Breast Cancer Awareness

Updated Category News Views 184

Jericho Wholesale and Shell Join Forces for a Cause Jericho Wholesale is proud to partner with Shell in the initiative Power Up for Pink Aid this October during Breast Cancer Awareness Month. This exciting campaign aims to assist underserved breast cancer patients and their families through vital financial support while raising awareness for the disease. What is Power Up...

Continue Reading
PMGC Holdings Implements Strategic Reverse Stock Split for Growth

Updated Category News Views 119

PMGC Holdings Announces Reverse Stock Split PMGC Holdings Inc. (NASDAQ: ELAB), based in Newport Beach, California, has recently unveiled an important strategic decision to carry out a 1-for-7 reverse stock split effective soon. This move reflects the company’s commitment to maintaining its compliance with Nasdaq’s listing requirements, which is essential for...

Continue Reading
Lynch Carpenter Takes Action on Anne Arundel Data Incident

Updated Category News Views 270

Lynch Carpenter's Response to the Data Breach Incident Recently, a cybersecurity incident was reported by Anne Arundel Dermatology, revealing that a significant breach of personal data has occurred. This disturbing event is said to have affected the personal information of numerous individuals, raising substantial concerns about data privacy. Details of the Cybersecurity...

Continue Reading